Please assess the completion status of the following clinical trial:

Trial Title: Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically-confirmed diagnosis of invasive breast cancer~* Clinical stage T2, N0 or N1, M0 (TNM Classification)~* Patients must be postmenopausal~* Tumors are estrogen receptor (ER) positive and human epidermal growth factor receptor (HER2) negative~* ECOG Performance status (PS) 0 or 1~* Patients must be able to swallow tablets and capsules~* Candidates for mastectomy or breast-conserving surgery~* Adequate bone marrow, liver and renal function~* Written informed consent was obtained from all patients before randomization.~Exclusion Criteria:~* Inoperable, bilateral or inflammatory breast cancer~* multiple carcinoma~* Personal history of invasive carcinoma~* Patients receive systemic therapy of corticosteroid~* Patients receive estrogen preparation or raloxifene~* Patients with other concurrent severe and/or uncontrolled medical disease~* Patients whom doctors judged inadequate to the enrollment of this study by other reasons.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ANA (Type: ACTIVE_COMPARATOR): None
- ANA+UFT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).